Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer. 2018

Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
Department of Gynecology and Obstetrics, Yantai Yuhuangding Hospital, Affiliated to Qingdao University, Yantai, Shandong 264000, P.R. China.

Accumulating data indicate that insulin resistance and unopposed estrogen are important risk factors of endometrial cancer (EC). Medroxyprogesterone 17‑acetate (MPA) has been used in the treatment of EC for many years. However, the therapeutic effect of this agent on EC has not been satisfactory. 36 arMetformin was recently reported to be a promising agent for the treatment of malignant diseases including EC. However, information on the synergistic effect of the two agents in EC is limited. With the aim to evaluate the synergistic effect of metformin and MPA, we conducted the present study in vitro and in vivo. We found that the combined application of metformin and MPA significantly inhibited the proliferation of the Ishikawa cells and arrested the cells in the G0/G1 phase. Furthermore, the apoptosis rate of the Ishikawa cells was significantly increased. In the animal study, the development of the xenograft tumors was significantly suppressed by the combined application of the two agents. Further investigation revealed that the synergistic inhibitory effect of the two agents on EC can be at least partly, explained by the decreased expression of cyclin D1 and cyclin E. The results of the current study provide novel insights into the treatment of EC.

UI MeSH Term Description Entries
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017258 Medroxyprogesterone Acetate A synthetic progestin that is derived from 17-hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by intramuscular injection and has also been used to treat breast and endometrial neoplasms. Depo-Medroxyprogesterone Acetate,Medroxyprogesterone 17-Acetate,Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6alpha)-,(6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione,6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate,Curretab,Cycrin,Depo-Provera,Farlutal,Gestapuran,Medroxyprogesterone 17-Acetate, (6 alpha,17 alpha)-Isomer,Medroxyprogesterone 17-Acetate, (6 beta)-Isomer,Perlutex,Provera,Veramix,6 alpha Methyl 17alpha hydroxyprogesterone Acetate,Depo Medroxyprogesterone Acetate,Depo Provera,DepoProvera,Medroxyprogesterone 17 Acetate
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
January 1989, Invasion & metastasis,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
September 1984, Cancer,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
July 1992, American journal of obstetrics and gynecology,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
October 2013, Zhonghua fu chan ke za zhi,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
February 1999, Gynecologic oncology,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
February 2016, Annals of oncology : official journal of the European Society for Medical Oncology,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
June 1992, Tumori,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
May 1969, American journal of obstetrics and gynecology,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
January 1990, Gynecologic and obstetric investigation,
Nan Mu, and Mei Dong, and Lei Li, and Min Xia, and Luyun Qv, and Yingmei Wang, and Changyan Dong, and Yonghua Chen, and Ying Zuo, and Jianqing Hou, and Fengxia Xue
March 1996, Oncology reports,
Copied contents to your clipboard!